{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:12Z","timestamp":1791357372328,"version":"4.3.1"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T00:00:00Z","timestamp":1386028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study is a meta\u2010analysis of inositol as a treatment for depression and anxiety disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Cochrane Library database, and PsycINFO were searched up to 14 August 2013. A systematic review and meta\u2010analysis of double\u2010blind, randomized, placebo\u2010controlled trials (RCTs) were conducted comparing inositol for depressed or anxiety disorder patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven RCTs in depression (two bipolar depression studies, one bipolar depression and major depressive disorder (MDD) study, two MDD studies, and two premenstrual dysphoric disorder (PMDD) studies) (<jats:italic>n<\/jats:italic>\u2009=\u2009242) were identified. Four RCTs in anxiety disorders (two obsessive\u2013compulsive disorder studies, one panic disorder study, and one posttraumatic stress disorder study) (<jats:italic>n<\/jats:italic>\u2009=\u200970) were also identified. There were no statistically significant effects of inositol on depressive, anxiety, and obsessive\u2013compulsive symptoms and discontinuation (all\u2010cause, side effects, and worsening psychiatric symptoms). However, inositol had marginally more responders in depression than placebo (<jats:italic>p<\/jats:italic>\u2009=\u20090.06), and inositol showed a trend towards superior efficacy for depressive symptoms in patients with PMDD (<jats:italic>p<\/jats:italic>\u2009=\u20090.07). Inositol marginally caused gastrointestinal upset compared with placebo (<jats:italic>p<\/jats:italic>\u2009=\u20090.06).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results suggest that inositol may be beneficial for depressed patients, especially those with PMDD. The main limitation of this report is that a small number of studies were included in this meta\u2010analysis. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2369","type":"journal-article","created":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T09:02:12Z","timestamp":1386061332000},"page":"55-63","source":"Crossref","is-referenced-by-count":79,"title":["A meta\u2010analysis of inositol for depression and anxiety disorders"],"prefix":"10.1002","volume":"29","author":[{"given":"Tomohiko","family":"Mukai","sequence":"first","affiliation":[{"name":"Department of Psychiatry, School of Medicine Fujita Health University  Toyoake Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine Fujita Health University  Toyoake Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine Fujita Health University  Toyoake Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine Fujita Health University  Toyoake Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2012.0535"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2012.0190"},{"key":"e_1_2_9_4_1","first-page":"65","article-title":"Reduced myo\u2010inositol levels in cerebrospinal fluid from patients with affective disorder","volume":"13","author":"Barkai AI","year":"1978","journal-title":"Biol Psychiatry"},{"key":"e_1_2_9_5_1","first-page":"167","article-title":"Inositol treatment in psychiatry","volume":"31","author":"Benjamin J","year":"1995","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.7.1084"},{"issue":"8","key":"e_1_2_9_7_1","first-page":"27","article-title":"Mixed anxiety and depression: from theory to practice","volume":"58","author":"Boulenger JP","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2011.02.011"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2000.020107.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.02.027"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2006.00303.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.11081302"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.9.1219"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145799001546"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1241"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110048007"},{"key":"e_1_2_9_18_1","volume-title":"Manual for the ECDEU Assessment Battery","author":"Guy W","year":"1970"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1522-7154(1996)2:1<51::AID-ANXI8>3.0.CO;2-G"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.5.792"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00145-0"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050200"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622970209150615"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.8.1148"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","unstructured":"TaylorMJ WilderH BhagwagarZ GeddesJ.2004.Inositol for depressive disorders. Cochrane database of systematic reviews.:CD004049.","DOI":"10.1002\/14651858.CD004049.pub2"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2369","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T23:35:39Z","timestamp":1696462539000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1002\/hup.2369"],"URL":"https:\/\/doi.org\/10.1002\/hup.2369","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,3]]}}}